2 results match your criteria: ""THEAGENIO" Anti-Cancer Hospital of Thessaloniki[Affiliation]"
Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study.
J Clin Med
April 2021
Department of Hematology, "THEAGENIO" Anti-Cancer Hospital of Thessaloniki, 54007 Thessaloniki, Greece.
The "POWERFUL" multicenter, retrospective, and prospective study investigated the effectiveness of pomalidomide plus low-dose dexamethasone (POM/LoDex) therapy in relapsed/refractory multiple myeloma in routine care in Greece. Ninety-nine eligible adult patients treated with POM/LoDex according to the approved label after having received ≥2 prior therapies, including lenalidomide and bortezomib, were consecutively enrolled between 16 November 2017 and 21 February 2019 in 18 hematology departments. Fifty patients (50.
View Article and Find Full Text PDFABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer.
Breast Cancer Res Treat
July 2020
First Department of Medical Oncology, AGIOS SAVVAS Athens General Hospital, Athens, Greece.
Purpose: The efficacy of nab-paclitaxel in patients with metastatic breast cancer (MBC) has been demonstrated in randomized clinical trials. However, real-world evidence on effectiveness remains limited.
Patients And Methods: The primary objective of this multicenter prospective study was to assess the overall response rate (ORR) of patients with MBC treated with nab-paclitaxel.